Molecule to Medicine

Molecule to Medicine (MTM) is a biotech venture builder that co-creates, builds, and scales drug discovery companies within a shared operational ecosystem, combining drug discovery expertise with shared infrastructure to enable rapid company formation.

UK operations are based at Milton Park, Abingdon, with a further pod in London.

Portfolio companies span oncology, immuno-oncology, inflammation, neurodegeneration, and cardiometabolic disease.